Surrozen, Inc. – NASDAQ:SRZN

Add to watchlist

$11.15

-2.75

-19.78%

Market open

Closed in about 6 hours

+50.60%

month

+50.60%

quarter

+63.16%

year

Market Cap	36.43M
Enterprise value	3.12M

P/E	-0.64
EV/Sales	N/A
EV/EBITDA	-0.04
Price/Sales	N/A
Price/Book	0.29
PEG ratio	-0.01
EPS	-18.38

Revenue	N/A
EBITDA	-35.44M
Income	-37.57M
Revenue Q/Q	N/A
Revenue Y/Y	-66.83%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Surrozen, Inc. (NASDAQ:SRZN): Profit margin
Jun 2023	0	-9.38M
Sep 2023	0	-10.44M
Dec 2023	4.14M	-8.91M	-214.98%
Mar 2024	0	-8.83M

Surrozen Financials Estimate

Q Y

Surrozen, Inc. (NASDAQ:SRZN): Analyst Estimates
2025	0	-38.3M
2026	0	-18.46M

Analysts Price target
Financials & Ratios estimates

Surrozen, Inc. (NASDAQ:SRZN): Earnings per share (EPS)
2024-04-03	-4.35	-0.45
2024-05-08	-4.25	-4.24

Surrozen, Inc. (NASDAQ:SRZN): Debt to assets
Jun 2023	63999000	8.94M	13.97%
Sep 2023	53973000	8.44M	15.64%
Dec 2023	46080000	8.14M	17.68%
Mar 2024	36716000	6.58M	17.92%

Surrozen, Inc. (NASDAQ:SRZN): Cash Flow
Jun 2023	-8.74M	17.24M	187K
Sep 2023	-10.13M	7.64M	-13K
Dec 2023	-7.31M	9.5M	141K
Mar 2024	-8.74M	-7K	0

Surrozen alternative data

Surrozen, Inc. (NASDAQ:SRZN): Employee count
Aug 2023	74
Sep 2023	74
Oct 2023	74
Nov 2023	74
Dec 2023	74
Jan 2024	74
Feb 2024	74
Mar 2024	74
Apr 2024	74
May 2024	42
Jun 2024	42
Jul 2024	42

Surrozen
Hedge Funds Holdings Q1 2023

100.00% 0.00%

of SRZN is owned by hedge funds

9 -17

hedge funds hold SRZN stock

1.80M -14.28M

shares is hold by hedge funds

SRZN hedge funds holdings changes

Surrozen, Inc. (NASDAQ:SRZN): Insider trades (number of shares)
Period	Buy	Sel
Apr 2024	4614282	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	4 Apr 2024	COLUMN GROUP III GP, LP 10 percent owner 10 percent owner	Common Stock	102,651	$15.5	$1,591,091
Purchase	4 Apr 2024	COLUMN GROUP III GP, LP 10 percent owner 10 percent owner	Common Stock	90,897	$15.5	$1,408,904
Purchase	4 Apr 2024	KUTZKEY TIM director, 10 percent owner: director, 10 percent owner:	Common Stock	102,651	$15.5	$1,591,091
Purchase	4 Apr 2024	KUTZKEY TIM director, 10 percent owner: director, 10 percent owner:	Common Stock	90,897	$15.5	$1,408,904
Purchase	4 Apr 2024	WILLIAMS CHARLES O officer: CFO and COO officer: CFO and COO	Series C Common Stock Warrant (right to buy)	5,712	$16	$91,392
Purchase	4 Apr 2024	WILLIAMS CHARLES O officer: CFO and COO officer: CFO and COO	Series D Common Stock Warrant (right to buy)	5,712	$16	$91,392
Purchase	4 Apr 2024	WILLIAMS CHARLES O officer: CFO and COO officer: CFO and COO	Series B Common Stock Warrant (right to buy)	1,603	$15.71	$25,183
Purchase	4 Apr 2024	WILLIAMS CHARLES O officer: CFO and COO officer: CFO and COO	Common Stock	1,474	$16.96	$24,999
Purchase	4 Apr 2024	WILLIAMS CHARLES O officer: CFO and COO officer: CFO and COO	Series A Common Stock Warrant (right to buy)	1,474	$16.96	$24,999
Purchase	4 Apr 2024	PARKER CRAIG C director, officer: Chief Executive Officer director, officer: Chief Execut..	Series C Common Stock Warrant (right to buy)	5,712	$16	$91,392

Surrozen
Earnings Call Transcripts

Quarter	Transcript
Q4 2022 25 Mar 2023	Q4 2022 Earnings Call Transcript

SRZN earnings call transcripts

Surrozen
Executives

Insider	Age	Compensation
Mr. Craig C. Parker M.B.A. (1962) Chief Executive Officer, Pres & Director	63	$553,500
Dr. Wen-Chen Yeh M.D., Ph.D. (1965) Chief Scientific Officer	60	$440,500
Mr. Charles Williams (1980) Chief Financial Officer	45	$70,490

Surrozen
Latest News

Wednesday, 6 November 2024
16:30	Surrozen to Present at Upcoming Healthcare Investor Conferences	globenewswire.com
09:00	Surrozen Provides Third Quarter 2024 Financial Results and Business Update	globenewswire.com
Monday, 4 November 2024
08:30	Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis	globenewswire.com
Tuesday, 24 September 2024
08:30	Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration	globenewswire.com
Monday, 12 August 2024
16:05	Surrozen Provides Second Quarter 2024 Financial Results and Business Update	globenewswire.com
Wednesday, 12 June 2024
08:30	Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling	globenewswire.com
Monday, 10 June 2024
08:30	Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan	globenewswire.com
Tuesday, 4 June 2024
08:30	Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis	globenewswire.com
Thursday, 9 May 2024
08:30	Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting	globenewswire.com
Wednesday, 8 May 2024
16:05	Surrozen Provides First Quarter 2024 Financial Results and Business Update	globenewswire.com
Sunday, 14 April 2024
09:25	Huge Insider Buying in Media by Warren Buffet and More	24/7 Wall Street
Monday, 8 May 2023
11:26	Here's Why Surrozen, Inc. (SRZN) Could be Great Choice for a Bottom Fisher	Zacks Investment Research
Thursday, 13 April 2023
09:08	5 Top Stocks Likely to Come Up With Earnings Beat	Zacks Investment Research
Wednesday, 12 April 2023
09:54	New Strong Buy Stocks for April 12th	Zacks Investment Research
Monday, 20 March 2023
16:30	Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023	GlobeNewsWire
Sunday, 12 February 2023
11:00	How to Diversify Your Penny Stock Investments	PennyStocks
Thursday, 9 February 2023
12:07	Penny Stocks To Buy? 4 Cheap Stocks To Watch Right Now	PennyStocks
Wednesday, 4 January 2023
16:41	Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference	GlobeNewsWire
Friday, 30 December 2022
13:33	Surrozen, Inc. (SRZN) Upgraded to Buy: Here's What You Should Know	Zacks Investment Research
Wednesday, 5 January 2022
08:00	Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference	GlobeNewsWire
Monday, 15 November 2021
08:00	Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of Surrozen stock today?

One share of Surrozen stock can currently be purchased for approximately $11.15.
When is Surrozen's next earnings date?

Unfortunately, Surrozen's (SRZN) next earnings date is currently unknown.
Does Surrozen pay dividends?

No, Surrozen does not pay dividends.
How much money does Surrozen make?

Surrozen has a market capitalization of 36.43M. Surrozen made a loss 43.04M US dollars in net income (profit) last year or -$4.24 on an earnings per share basis.
What is Surrozen's stock symbol?

Surrozen, Inc. is traded on the NASDAQ under the ticker symbol "SRZN".
What is Surrozen's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Surrozen?

Shares of Surrozen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Surrozen's key executives?
Surrozen's management team includes the following people:
- Mr. Craig C. Parker M.B.A. Chief Executive Officer, Pres & Director(age: 63, pay: $553,500)
- Dr. Wen-Chen Yeh M.D., Ph.D. Chief Scientific Officer(age: 60, pay: $440,500)
- Mr. Charles Williams Chief Financial Officer(age: 45, pay: $70,490)
How many employees does Surrozen have?

As Jul 2024, Surrozen employs 42 workers, which is 43% less then previous quarter.
When Surrozen went public?

Surrozen, Inc. is publicly traded company for more then 4 years since IPO on 11 Jan 2021.
What is Surrozen's official website?

The official website for Surrozen is surrozen.com.
Where are Surrozen's headquarters?

Surrozen is headquartered at 171 Oyster Point Boulevard, South San Francisco, CA.
How can i contact Surrozen?

Surrozen's mailing address is 171 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +65 04899000.

Surrozen, Inc.

surrozen.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

+65 04899000

171 Oyster Point Boulevard
South San Francisco, CA 94080

CIK: 0001824893
ISIN: US86889P2083
CUSIP: 86889P109